Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways

J. A. Kelber, A. D. Panopoulos, G. Shani, E. C. Booker, J. C. Belmonte, W. W. Vale, P. C. Gray

Research output: Contribution to journalArticlepeer-review

155 Scopus citations

Abstract

Cripto is a developmental oncoprotein that signals via mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/Akt and Smad2/3 pathways. However, the molecular basis for Cripto coupling to these pathways during embryogenesis and tumorigenesis is not fully understood. In this regard, we recently demonstrated that Cripto forms a cell surface complex with the HSP70 family member glucose-regulated protein-78 (GRP78). Here, we provide novel functional evidence demonstrating that cell surface GRP78 is a necessary mediator of Cripto signaling in human tumor, mammary epithelial and embryonic stem cells. We show that targeted disruption of the cell surface Cripto/GRP78 complex using shRNAs or GRP78 immunoneutralization precludes Cripto activation of MAPK/PI3K pathways and modulation of activin-A, activin-B, Nodal and transforming growth factor-Β1 signaling. We further demonstrate that blockade of Cripto binding to cell surface GRP78 prevents Cripto from increasing cellular proliferation, downregulating E-Cadherin, decreasing cell adhesion and promoting pro-proliferative responses to activin-A and Nodal. Thus, disrupting the Cripto/GRP78 binding interface blocks oncogenic Cripto signaling and may have important therapeutic value in the treatment of cancer.

Original languageEnglish (US)
Pages (from-to)2324-2336
Number of pages13
JournalOncogene
Volume28
Issue number24
DOIs
StatePublished - Jun 18 2009
Externally publishedYes

Bibliographical note

Funding Information:
Dr Vale’s work has been funded by the NIH. He is a cofounder, consultant, equity holder, member of the Board of Directors and Scientific Advisory Board of Neurocrine

Funding Information:
This work was supported by NCI, National Institutes of Health, Grant R01CA107420, the Foundation for Medical research, Inc., and the Robert J Jr and Helen Kleberg

Keywords

  • Akt
  • Cancer
  • Cripto
  • GRP78
  • MAPK
  • Stem cell
  • TGF-β

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint

Dive into the research topics of 'Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways'. Together they form a unique fingerprint.

Cite this